Neurotype

Market position

Neurotype addresses the UK ADHD and autism assessment backlog, which it cites at 800,000 people and projected to reach one million within two years, targeting the report-writing stage that it says 96% of clinicians identify as the biggest constraint on capacity.

Neurotype positions itself against two adjacent categories: transcription or note-capture tools, which it says do not address diagnostic synthesis, and broad clinic or practice-management software. Its stated differentiators are domain-specific design around neurodevelopmental diagnostic reasoning and evidence structure, compatibility with a clinic's existing templates, protocols and workflow without replacement, clinical co-design by a senior clinical psychologist, and output intended to be personalised, neuroaffirming and strengths-based while handling nuances such as conflicting evidence and masking.

Technology

AI designed for diagnostic reasoning that classifies uploaded case documents and assembles structured report drafts matched to a clinic's format, embedded in a clinician-in-the-loop review interface organised into sections. Infrastructure is UK-hosted and described as GDPR compliant, with ICO registration, Cyber Essentials and Cyber Essentials Plus certification and NHS DSPT completion; third-party processors include cloud and collaboration services.

Go-to-market

Direct sales to clinics and healthcare providers via demo booking on the company website, supported by clinician testimonials and trust signals including ICO registration, Cyber Essentials and Cyber Essentials Plus certification and the NHS Data Security and Protection Toolkit.

NHS organisations and private clinics carrying out ADHD and autism diagnostic assessments, and the clinicians within them - clinical psychologists, psychiatrists and other diagnostic clinicians - plus clinic administrators and managers.

Geography

UK-based and UK-hosted, with a registered office in London. The platform is used by diagnostic clinicians across the UK and Ireland. Some sub-processors may involve transfers outside the UK/EEA under Standard Contractual Clauses or the UK IDTA.

History

NEUROTYPE LTD was incorporated in England on 6 June 2025 under the name NEUROTYPE AI LTD, and was renamed NEUROTYPE LTD on 28 July 2025. It is a private limited company registered under SIC code 62020 (information technology consultancy activities), with a registered office c/o Second Home, 68-80 Hanbury Street, London E1 5JL. Its first accounts are made up to 30 June 2026. By 2026 the platform was in use by clinicians in the UK and Ireland, with published testimonials from a consultant psychiatrist and other diagnostic clinicians.

Risks & controversies

The platform generates AI drafts of high-stakes clinical documentation, and the interface itself flags that content is "Generated with AI - please review before finalizing"; responsibility for judgment and sign-off rests with the clinician. Processing of patient health data places the company under UK GDPR obligations as a data processor, with the healthcare provider as controller.